TRAIL-modified, doxorubicin-embedded periodic mesoporous organosilica nanoparticles for targeted drug delivery and efficient antitumor immunotherapy

Feng, Xinyao; Li, Fangshen; Zhang, Liangliang; Liu, Wenmo; Wang, Xupu; Zhu, Rui; Qiao, Zhen‐An; Yu, Bin; Yu, Xianghui

doi:10.1016/j.actbio.2022.03.001

Cited by 23 publications

(21 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TRAIL, fused with the C-terminus fiber shaft of human adenovirus type 5 (HA5ST) and modified with cysteine, was conjugated on the maleimide-modified PMO surface, and the fabricated PMO-hT was loaded with doxorubicin in the PMO channels to obtain DOX@PMO-hT. This drug delivery system showed a synergistic effect due to the induction of tumor death through the TRAIL apoptotic pathway and immunogenic cell death in tumors, together with activating immune cells through the immunomodulatory functions of PMOs [ 43 ]. Such a drug delivery nanovehicle, which combines the properties of inorganic and organic materials and synergistically modulates immunity, may gain further development for anticancer treatment.…”

Section: Inorganic Nanoparticles Modified With Trail Pathway-targetin...mentioning

confidence: 99%

Recent Advances in the Development of Nanodelivery Systems Targeting the TRAIL Death Receptor Pathway

2023

View full text Add to dashboard Cite

The TRAIL (TNF-related apoptosis-inducing ligand) apoptotic pathway is extensively exploited in the development of targeted antitumor therapy due to TRAIL specificity towards its cognate receptors, namely death receptors DR4 and DR5. Although therapies targeting the TRAIL pathway have encountered many obstacles in attempts at clinical implementation for cancer treatment, the unique features of the TRAIL signaling pathway continue to attract the attention of researchers. Special attention is paid to the design of novel nanoscaled delivery systems, primarily aimed at increasing the valency of the ligand for improved death receptor clustering that enhances apoptotic signaling. Optionally, complex nanoformulations can allow the encapsulation of several therapeutic molecules for a combined synergistic effect, for example, chemotherapeutic agents or photosensitizers. Scaffolds for the developed nanodelivery systems are fabricated by a wide range of conventional clinically approved materials and innovative ones, including metals, carbon, lipids, polymers, nanogels, protein nanocages, virus-based nanoparticles, dendrimers, DNA origami nanostructures, and their complex combinations. Most nanotherapeutics targeting the TRAIL pathway are aimed at tumor therapy and theranostics. However, given the wide spectrum of action of TRAIL due to its natural role in immune system homeostasis, other therapeutic areas are also involved, such as liver fibrosis, rheumatoid arthritis, Alzheimer’s disease, and inflammatory diseases caused by bacterial infections. This review summarizes the recent innovative developments in the design of nanodelivery systems modified with TRAIL pathway-targeting ligands.

show abstract

Section: Inorganic Nanoparticles Modified With Trail Pathway-targetin...mentioning

confidence: 99%

Recent Advances in the Development of Nanodelivery Systems Targeting the TRAIL Death Receptor Pathway

2023

View full text Add to dashboard Cite

show abstract

“…Feng and colleagues addressed the question of whether NP-based TRAIL delivery could instigate an anti-tumor immune response, thus facilitating long-term disease control using another polymer NP, periodic mesoporous organosilica (PMO) [ 262 ]. DOX was encapsulated into a PMO NP and the NP surface was modified with TRAIL.…”

Section: Trail Formulations To Mimic Membrane-bound Trailmentioning

confidence: 99%

“…DOX was encapsulated into a PMO NP and the NP surface was modified with TRAIL. This nanoplatform induced an immune response by activating dendritic cells, CD4 + and CD8 + T cells and inhibited tumor growth in a breast cancer mouse model [ 262 ].…”

Section: Trail Formulations To Mimic Membrane-bound Trailmentioning

confidence: 99%

TRAIL in the Treatment of Cancer: From Soluble Cytokine to Nanosystems

Zeinabad

Szegezdi

2022

Cancers

View full text Add to dashboard Cite

The death ligand tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), a member of the TNF cytokine superfamily, has long been recognized for its potential as a cancer therapeutic due to its low toxicity against normal cells. However, its translation into a therapeutic molecule has not been successful to date, due to its short in vivo half-life associated with insufficient tumor accumulation and resistance of tumor cells to TRAIL-induced killing. Nanotechnology has the capacity to offer solutions to these limitations. This review provides a perspective and a critical assessment of the most promising approaches to realize TRAIL’s potential as an anticancer therapeutic, including the development of fusion constructs, encapsulation, nanoparticle functionalization and tumor-targeting, and discusses the current challenges and future perspectives.

show abstract

“…Numerous recent studies have been conducted on TRAIL [ 112 ]. For example, Feng et al used a targeted drug delivery system with promising results, showing that TRAIL enhanced the targeting ability of nanoparticles and acted synergistically with DOX-inhibiting tumor cells [ 113 ]. Pumilio-1 (PUM1) is an RNA-binding pumilio protein with a dramatically increased expression level in various tumor tissues.…”

Section: Natural Products Overcome Autophagy-mediated Tumor Drug Resi...mentioning

confidence: 99%

Focusing on the Role of Natural Products in Overcoming Cancer Drug Resistance: An Autophagy-Based Perspective

Yao

Feng

et al. 2022

Biomolecules

View full text Add to dashboard Cite

Autophagy is a critical cellular adaptive response in tumor formation. Nutritional deficiency and hypoxia exacerbate autophagic flux in established malignancies, promoting tumor cell proliferation, migration, metastasis, and resistance to therapeutic interventions. Pro-survival autophagy inhibition may be a promising treatment option for advanced cancer. Furthermore, excessive or persistent autophagy is cytotoxic, resulting in tumor cell death. Targeted autophagy activation has also shown significant promise in the fight against tumor drug resistance. Several research groups have examined the ability of natural products (NPs) such as alkaloids, terpenoids, polyphenols, and anthraquinones to serve as autophagy inhibitors or activators. The data support the capacity of NPs that promote lethal autophagy or inhibit pro-survival autophagy from being employed against tumor drug resistance. This paper discusses the potential applications of NPs that regulate autophagy in the fight against tumor drug resistance, some limitations of the current studies, and future research needs and priorities.

show abstract

TRAIL-modified, doxorubicin-embedded periodic mesoporous organosilica nanoparticles for targeted drug delivery and efficient antitumor immunotherapy

Cited by 23 publications

References 40 publications

Recent Advances in the Development of Nanodelivery Systems Targeting the TRAIL Death Receptor Pathway

Recent Advances in the Development of Nanodelivery Systems Targeting the TRAIL Death Receptor Pathway

TRAIL in the Treatment of Cancer: From Soluble Cytokine to Nanosystems

Focusing on the Role of Natural Products in Overcoming Cancer Drug Resistance: An Autophagy-Based Perspective

Contact Info

Product

Resources

About